Physician profile
Radames Sierra Zorita
NPI 1669457875
$427,699.85
in general payments reported to CMS, 2019-2025
33 companies · $41K in 2025
The $41K reported for 2025 was more than what 95% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147K · 2020: $25K · 2021: $45K · 2022: $76K · 2023: $51K · 2024: $43K · 2025: $41K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $67K · Honoraria: $18K · Consulting Fee: $18K · Food and Beverage: $17K · Travel and Lodging: $15K · Education: $257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $67,101.50 |
| Honoraria | $18,057.50 |
| Consulting Fee | $17,952.50 |
| Food and Beverage | $16,913.69 |
| Travel and Lodging | $14,603.25 |
| Education | $257.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $153,526.56 | 2019-2025 | Krystexxa, Otezla, Evenity |
| Abbvie INC. | $69,902.22 | 2019-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $54,959.56 | 2019-2025 | |
| Horizon Therapeutics Plc | $42,422.79 | 2019-2023 | Krystexxa |
| Radius Health, INC. | $31,823.12 | 2019-2025 | Tymlos |
| E.R. Squibb & Sons, L.L.C. | $10,228.28 | 2019-2025 | Orencia, Sotyktu |
| Celgene Corporation | $10,093.32 | 2019-2024 | |
| Ucb, INC. | $9,021.46 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $8,152.28 | 2019-2022 | |
| Genzyme Corporation | $7,610.08 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $6,442.19 | 2019-2025 | Winrevair |
| Lilly USA, LLC | $6,202.82 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $3,944.33 | 2019 | |
| Janssen Pharmaceuticals, INC | $3,760.82 | 2019-2025 | Tremfya, Stelara, Simponi |
| Pfizer Pharmaceuticals LLC | $2,940.43 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pbg Puerto Rico LLC | $1,351.74 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $1,098.39 | 2021-2025 | Acthar |
| Astrazeneca Pharmaceuticals Lp | $1,047.66 | 2023-2025 | Saphnelo, Fasenra |
| Ferring Pharmaceuticals INC. | $1,007.95 | 2019-2020 | |
| Glaxosmithkline, LLC. | $562.88 | 2019-2025 | Benlysta |
| Eli Lilly Export S.A. Puerto Rico Branch | $418.53 | 2019-2024 | Taltz |
| Genentech, INC. | $263.38 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.58 | 2023-2024 | Cyltezo, Ofev |
| Janssen Biotech, INC. | $125.29 | 2025 | Tremfya, Simponi Aria |
| Sanofi-Aventis U.S. LLC | $122.99 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $121.00 | 2021 | |
| Hikma Pharmaceuticals USA | $87.19 | 2019-2021 | |
| Organon LLC | $61.84 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $54.99 | 2025 | Uptravi, Opsumit |
| Ani Pharmaceuticals, INC. | $50.00 | 2023 | Purified Cortrophin Gel |
| Alexion Pharmaceuticals, INC. | $46.54 | 2019 | |
| Sobi, INC | $44.78 | 2025 | |
| Mallinckrodt Enterprises LLC | $18.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Radames Sierra Zorita listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.